CAS 1454585-06-8

N-((4,5-difluoro-1H-benzo[d]imidazol-2-yl)methyl)-9-(3-fluorophenyl)-2-morpholino-9H-purin-6-amine

CAS : 1454585-06-8

Formule : C₂₃H₁₉F₃N₈O

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 480.4452

Ref: IN-DA00ABTA

N-((6,7-Difluoro-1H-Benzo[D]Imidazol-2-Yl)Methyl)-9-(3-Fluorophenyl)-2-Morpholino-9H-Purin-6-Amine

CAS : 1454585-06-8

N-((6,7-Difluoro-1H-Benzo[D]Imidazol-2-Yl)Methyl)-9-(3-Fluorophenyl)-2-Morpholino-9H-Purin-6-Amine

Degré de pureté : 99%

Masse moléculaire : 480.45g/mol

Ref: 54-PC108734

SR-3029

CAS : 1454585-06-8

SR-3029

Degré de pureté : ≥98%

Masse moléculaire : 480.45g/mol

Ref: 54-BUP01753

SR-3029

CAS : 1454585-06-8

SR-3029 is a potent and highly specific CK1δ/CK1ε inhibitor.

Formule : C₂₃H₁₉F₃N₈O

Degré de pureté : 99.64%

Couleur et forme : Solid

Masse moléculaire : 480.45

Ref: TM-T3972

SR 3029

CAS : 1454585-06-8

SR 3029 is a small-molecule drug that has potent antitumor activity. It inhibits cancer cell growth by inhibiting the signal pathways that regulate epidermal growth factor (EGF) production. SR 3029 is effective in animal models of metastatic colorectal cancer and skin tumor formation. In addition, SR 3029 has been shown to inhibit platinum-based chemotherapy, which may be due to its ability to target the cancer tissues and prevent metastasis.

Formule : C₂₃H₁₉F₃N₈O

Degré de pureté : Min. 95%

Masse moléculaire : 480.45 g/mol

Ref: 3D-EIC58506